Aligos (ALGS) stock rating confirmed; HBV progress noted

H.C. Wainwright has reiterated its stock rating for Aligos Therapeutics (ALGS) in light of the company's advancements concerning hepatitis B virus (HBV). The firm has acknowledged the company's ongoing clinical efforts and studies. This confirmation from a financial analyst can influence market perceptions of Aligos and impact trading volumes. The positive outlook on their HBV progress may encourage investor interest in Aligos stock moving forward.